$CYTR Kim Stratton, Chief Executive Officer of Orphazyme, said, “This is the second of our studies to show a positive clinical effect of arimoclomol in lysosomal storage diseases. Together with the phase 2/3 trial results in Niemann-Pick disease Type C (NPC), these data reinforce the potential of Heat-Shock Protein amplification and give us further confidence in arimoclomol as a potential game-changer for patients with lysosomal storage and neurodegenerative diseases.